Clever Culture Systems secures a follow-up order from Novo Nordisk for two APAS Independence instruments, marking a critical step toward broader global deployment and signalling expected sales growth from FY27.
- Novo Nordisk increases APAS Independence instruments to three
- Order includes custom LIMS integration software development
- Formal validation set to enable routine GMP laboratory use
- Expansion with existing pharma customers to drive FY27 sales
- APAS technology evaluated positively over past 12 months
Novo Nordisk Commits to Broader APAS Deployment
Clever Culture Systems Ltd (ASX:CC5) has landed a significant follow-up order from pharmaceutical giant Novo Nordisk, which has purchased two additional APAS Independence instruments. This purchase lifts Novo Nordisk’s installed base to three units, consolidating its commitment to the AI-driven microbiology automation technology. The new instruments will be installed at a single Danish site to support formal global validation, a prerequisite for transitioning APAS technology into routine use under stringent Good Manufacturing Practice (GMP) regulations.
Integration with Global Laboratory Systems
Beyond hardware, the order includes development of advanced interface software between APAS and Novo Nordisk’s global Laboratory Information Management System (LIMS). This bi-directional integration aims to streamline environmental monitoring workflows by enabling intelligent sorting of culture plates. Such customisation reflects the high regulatory and operational standards in sterile drug manufacturing, where data integrity and patient safety are paramount.
Validation Milestone Clears Path for Expansion
The Danish site validation marks the final technology performance milestone for Novo Nordisk before potential wider deployment across its manufacturing network. The initial APAS instrument was acquired in July 2025 for a global evaluation phase, which concluded successfully. This progression exemplifies Clever Culture Systems’ 'Land and Expand' strategy, targeting large pharmaceutical manufacturers with multi-site operations and moving them from evaluation to routine GMP use.
Broader Pharmaceutical Customer Momentum
Clever Culture Systems has now installed APAS Independence instruments with eight global pharmaceutical manufacturers, each at varying stages of adoption. The company anticipates that expansion within this established customer base will be the primary driver of a step-change in sales starting in FY27. This follows a year of growing validation and deployment activity, supported by a pipeline of qualified sales opportunities and a growing installed base worldwide.
Strategic Implications for FY27 and Beyond
CEO Brent Barnes emphasised the importance of this order as evidence of APAS technology’s performance and regulatory readiness. The integration with LIMS and the move toward formal validation underscore the company’s focus on embedding its technology within complex pharmaceutical manufacturing environments. While the timeline for broader rollout beyond Denmark remains unspecified, this development aligns with CCS’s recent momentum and expectations for increased sales driven by existing customers expanding their use of APAS systems.
Bottom Line?
Novo Nordisk’s order and integration plans mark a pivotal step in CCS’s pharma expansion, setting the stage for FY27 sales growth as validation hurdles are cleared.
Questions in the middle?
- How quickly will Novo Nordisk complete validation and begin broader APAS deployment?
- Will other pharmaceutical customers follow Novo Nordisk’s lead in ordering additional instruments?
- How effective will the new LIMS integration be in driving operational efficiencies and customer value?